Jazz Pharmaceuticals JAZZ Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's operating cash flow?
- Jazz Pharmaceuticals (JAZZ) reported operating cash flow of $408.2M in Q1 2026.
- How has Jazz Pharmaceuticals's operating cash flow changed year-over-year?
- Jazz Pharmaceuticals's operating cash flow decreased by 5.0% year-over-year, from $429.8M to $408.2M.
- What is the long-term trend for Jazz Pharmaceuticals's operating cash flow?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's operating cash flow has grown at a 14.9% compound annual growth rate (CAGR), from $778.51M to $1.36B.
- What does operating cash flow mean?
- The net amount of cash generated from the company's day-to-day business activities.
- How do you interpret operating cash flow?
- Higher values indicate stronger operational health and ability to self-fund.
- How does operating cash flow compare across companies?
- The gold standard for operational performance; essential for comparing cash-generating ability across all public companies.